Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer


In Partnership With:

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

Bradley R. Corr, MD, assistant professor of gynecologic oncology, Division of Gynecologic Oncology, University of Colorado Anschutz Medical Campus, UCHealth, discusses the utilization of molecular profiling in endometrial cancer.

Molecular profiling has quickly evolved to be the standard of care for patients with endometrial cancer, Corr says. This is because molecular profiling continues to dictate thoseappropriate therapies for patients as the field advances significantly, Corr explains. Moreover, the National Comprehensive Cancer Network guidelines recommend molecular testing for patients with standard, mismatch repair deficient, POLE-mutated, and p53-mutated endometrial cancers, Corr adds.

As these recommendations develop, molecular markers are being identified, as areefficacious therapies targeted toward these molecular markers, Corr continues. This is helping to not only dictate which therapies are used, but also which tumors don't require therapy, Corr says. As such, molecular testing is informing clinical trial development, as well as informing treatment selecting for patients with endometrial cancer, Corr concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS